Neurocrine Biosciences, Inc. is a commercial-stage biopharmaceutical company that develops treatments for neurological, endocrine, and psychiatric disorders. The company's business model centers on the research, development, and commercialization of small molecule drugs, alongside strategic partnerships for pipeline expansion and global distribution.
Neurocrine's primary revenue source is INGREZZA (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor used to treat adults with tardive dyskinesia and chorea associated with Huntington's disease. In 2025, INGREZZA generated approximately $2.51 billion in net product sales, accounting for nearly 89% of the company's total net product revenue. The company's second major commercial product is CRENESSITY (crinecerfont), a corticotropin-releasing factor type 1 (CRF1) receptor antagonist approved for classic congenital adrenal hyperplasia (CAH), which generated approximately $301 million (about 11% of net product revenue) in 2025.
Geographically, Neurocrine commercializes its products directly in the United States through a specialized sales network. For international markets, the company leverages strategic partnerships, such as its agreement with Mitsubishi Tanabe Pharma for valbenazine in Asia and AbbVie for the global commercialization of elagolix (marketed as Orilissa for endometriosis and Oriahnn for uterine fibroids).
Neurocrine's competitive position is supported by its focus on validated biological pathways, particularly VMAT2 and CRF receptors. The company maintains a clinical pipeline spanning multiple therapeutic modalities, including next-generation VMAT2 inhibitors, muscarinic agonists for schizophrenia and Alzheimer's psychosis, and early-stage gene therapy programs for Parkinson's disease and Friedreich's ataxia developed in collaboration with Voyager Therapeutics.
